Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, ...

Products are independently selected by our editors. We may earn an affiliate commission from links. “Today, it’s really just going to be about the eye,” Alex Consani says, preparing to walk ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

20% of patients had a best clinical response of SD Elotuzumab (HuLuc63), a humanized mAb CS1 High expression on the surface of MM cell lines and on plasma cells from MM patients 24 ADCC against MM ...

Jan. 3, 2025 — Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, ... Enzyme Promoting Tumor Growth ...